Kyverna Therapeutics, Inc.
corporate_fare Company Profile
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 28 items for KYTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for KYTX spans 8-K, 10-Q.
Recent high-impact activity:
- Kyverna Posts Q3 Loss of $41.9M, Ends Quarter With $170.6M and BLA Filed for Miv-cel
- Kyverna Completes First-Ever Autoimmune CAR-T BLA Filing, Seeks Priority Review in Stiff Person Syndrome
- Kyverna's miv-cel Shows Two-Year Disability Benefit in Progressive MS
- Kyverna Reports Durable One-Year SPS and gMG Data; BLA Filing on Track for Q4 2026
- Kyverna's Miv-cel Shows Durable One-Year Responses in SPS and gMG, BLA on Track for Q4
Financial Snapshot
Short Interest & Short Volume
11.60 days to coverFINRA reported short interest of 9,095,664 shares in KYTX as of the October 30, 2026 settlement, a 4.7% decrease from the prior period — about 11.6 days to cover at its recent average daily volume. On November 20, 2026, 60.6% of KYTX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.